Could Kineret® reduce inflammation in stroke patients?

In a recently published study in Stroke, researchers have revealed that the anti-inflammatory drug, Kineret®, could reduce inflammation when given to patients in the early stages of a stroke.

Kineret is currently licensed for treatment of rheumatoid arthritis and works by blocking the actions of IL-1, which is released into the body following injury caused by a stroke.

The single-center, double-blind, randomized, placebo-controlled Phase II trial (SCIL-STROKE) was funded by the Stroke Association and follows earlier research that demonstrate the drug reduces inflammation in stroke and subarachnoid hemorrhage patients.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please Login or Register to view this area.